PD-L1 Assessment for Targeted Therapy Testing in Cancer

Applied Immunohistochemistry and Molecular Morphology - United States
doi 10.1097/pai.0000000000000472
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability

Archives of Pathology and Laboratory Medicine
MedicineForensic MedicinePathologyMedical Laboratory Technology
2016English

Aspirin‐targeted PD‐L1 in Lung Cancer Growth Inhibition

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2020English

7. PD-L1 in Triple Negative Breast Cancer – Optimal Testing for Therapeutic Efficacy

Pathology
Forensic MedicinePathology
2020English

PD-1/PD-L1 Blockade: A New Promising Therapy for the Treatment of Pancreatic Cancer?

Pancreas - Open Journal
2018English

Rationale of Combination of Anti-Pd-1/Pd-L1 Antibody Therapy and Radiotherapy for Cancer Treatment

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2020English

Design of PD-L1 Inhibitors for Lung Cancer

Bioinformation
2019English

Oncolytic Virus and PD-1/PD-L1 Blockade Combination Therapy

Oncolytic Virotherapy
2018English

Understanding the Role of PD-L1/PD1 Pathway Blockade and Autophagy in Cancer Therapy

OncoTargets and Therapy
OncologyPharmacology
2017English

PD-L1 Expression in Triple-Negative Breast Cancer

Cancer immunology research
Cancer ResearchImmunology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy